Preparation and Evaluation of Chitosan Coated PLGA Nanoparticles Encapsulating Ivosidenib with Enhanced Cytotoxicity Against Human Liver Cancer Cells
DOI: https://doi.org/10.2147/ijn.s452989
IF: 7.033
2024-04-09
International Journal of Nanomedicine
Abstract:Bader B Alsulays, Alhussain H Aodah, Mohammad Muqtader Ahmed, Md Khalid Anwer Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, 11942, Saudi Arabia Correspondence: Bader B Alsulays, Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, P.O. Box 173, Al-Kharj, Saudi Arabia, Tel +966-554112830, Email Purpose: Ivosidenib (IVO), an isocitrate dehydrogenase-1 (IDH1) used for treatment of acute myeloid leukemia (AML) and cholangiocarcinoma. However, poor solubility, low bioavailability, high dose and side effects limit clinical application of IVO. Methods: Ivosidenib-loaded PLGA nanoparticles (IVO-PLGA-NPs) and Ivosidenib-loaded chitosan coated PLGA nanoparticles (IVO-CS-PLGA-NPs) were prepared using emulsification and solvent evaporation method for the treatment of liver cancer. Results: The developed IVO-PLGA-NPs were evaluated for their particle size (171.7± 4.9 nm), PDI (0.333), ZP (− 23.0± 5.8 mV), EE (96.3± 4.3%), and DL (9.66± 1.1%); similarly, the IVO-CS-PLGA-NPs were evaluated for their particle size (177.3± 5.2 nm), PDI (0.311), ZP +25.9± 5.7 mV, EE (90.8± 5.7%), and DL (9.42± 0.7%). The chitosan coating of IVO-PLGA-NPs was evidenced by an increase in mean particle size and positive ZP value. Because of the chitosan coating, the IVO-CS-PLGA-NPs showed a more stable and prolonged release of IVO than IVO-PLGA-NPs. In comparison to pure-IVO, the IVO-PLGA-NPs and IVO-CS-PLGA-NPs were found to be more effective against HepG2 cells, with IC 50 values for the MTT assay being approximately half of those of pure-IVO. In HepG2 cells, the expressions of caspase-3, caspase-9, and p53 were significantly (p < 0.05) elevated. Conclusion: Overall, these findings suggest that chitosan coating of IVO-PLGA-NPs improves the delivery and efficacy of ivosidenib in liver cancer treatment. Keywords: polymers, characterization, bioavailability, sustained release, caspase Liver cancer is one of the most common cancers globally, and one of the highest cause of the cancers related death. Most of the liver cancer cases were in the form of Hepatocellular carcinoma (HCC). Lack of effective treatment is the main reason of high mortality rate. The classical chemotherapy is insufficient and there is a significant chemoresistance of HCCs. 1–3 Ivosidenib, is a newly FDA approved drug for the treatment of adults with relapsed or refractory acute myeloid leukemia. It is an inhibitor of mutated cytosolic isocitrate dehydrogenase 1 (IDH1). Cholangiocarcinoma, solid tumor and other tumors are other indications of Ivosidenib, which are now undergoing clinical development worldwide. 4–6 It is classified as BCS class II drug with poor solubility and high permeability. 7 The poor aqueous solubility will further affect the bioavailability of the drug and limit its clinical effect. In order to improve the solubility of poorly soluble drug, many techniques, such as solid dispersion, salt formation, complexation, and nanoparticle were employed. Among these techniques, nanoparticle has gained considerable attention and extensively investigated in the pharmaceutical industry. Due to its advantages in improving drug solubility, bioavailability, stability and high encapsulation efficiency, polymeric nanoparticles were frequently used in drug development. 8,9 Nanostructures offer a promising solution to the challenges faced in the treatment of liver cancer, particularly in combating drug resistance. The ability of nanostructures to deliver drugs directly to cancer cells can help overcome issues such as limited drug penetration and efficacy, as well as reduce systemic toxicity. 10 Biodegradable polymers which used in polymeric nanoparticle formulation have some benefits of being less toxic and its role in improving the physiochemical properties of poorly soluble drugs. PLGA, short for poly(lactic-co-glycolic acid), is a remarkable polymer that has gained considerable recognition in the realm of biomedical research and pharmaceutical development. It is US-FDA approved copolymer, making it a highly trusted choice for the preparation of various polymeric nanoparticle-based formulations. Many applications of this polymer including enhancing the solubility, bioavailability, and stability have been reported. PLGA polymers play a crucial role in delivering anticancer drugs directly to tumor sites, maximizing treatment efficacy while minimizing side effects. The ability of PLGA to encapsulate and release drugs in a controlled manner enhances the therapeutic outcomes of cancer treatments. 11,12 Although, many advantages of PLGA NPs, it impart negative surface potential, which decrease the mucoadhesive properties as well as -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology